Esperion Therape Financials
This page shows Esperion Therape (ESPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Esperion’s revenue scale-up has covered core operating costs, but a heavy financing burden still blocks full profitability.
Losses now sit mainly below the operating line: the company kept positive operating income, but interest expense still ran above operating profit, while operating cash flow improved from-$23.7M to-$13.1M . That combination means the commercial engine is no longer the main problem; the remaining drag comes from how the business is financed and from cash tied up as sales expand.
Cost structure shifted materially over the last three years. R&D fell to
Liquidity is better than solvency here. A current ratio of 1.5x and cash of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Esperion Therape's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Esperion Therape has an operating margin of 14.9%, meaning the company retains $15 of operating profit per $100 of revenue. This below-average margin results in a low score of 24/100, suggesting thin profitability after operating expenses. This is down from 16.4% the prior year.
Esperion Therape's revenue surged 21.3% year-over-year to $403.1M, reflecting rapid business expansion. This strong growth earns a score of 97/100.
Esperion Therape's current ratio of 1.54 indicates adequate short-term liquidity, earning a score of 42/100. The company can meet its near-term obligations, though with limited headroom.
While Esperion Therape generated -$13.1M in operating cash flow, capex of $0 consumed most of it, leaving -$13.1M in free cash flow. This results in a low score of 11/100, reflecting heavy capital investment rather than weak cash generation.
Esperion Therape scores -2.53, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($822.0M) relative to total liabilities ($767.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Esperion Therape passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Esperion Therape generates $0.58 in operating cash flow (-$13.1M OCF vs -$22.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Esperion Therape earns $0.7 in operating income for every $1 of interest expense ($60.3M vs $84.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Esperion Therape generated $403.1M in revenue in fiscal year 2025. This represents an increase of 21.3% from the prior year.
Esperion Therape's EBITDA was $60.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.9% from the prior year.
Esperion Therape reported -$22.7M in net income in fiscal year 2025. This represents an increase of 56.2% from the prior year.
Esperion Therape earned $-0.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 60.7% from the prior year.
Cash & Balance Sheet
Esperion Therape generated -$13.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.4% from the prior year.
Esperion Therape held $167.9M in cash against $0 in long-term debt as of fiscal year 2025.
Margins & Returns
Esperion Therape's operating margin was 14.9% in fiscal year 2025, reflecting core business profitability. This is down 1.4 percentage points from the prior year.
Esperion Therape's net profit margin was -5.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.9 percentage points from the prior year.
Capital Allocation
Esperion Therape invested $47.9M in research and development in fiscal year 2025. This represents an increase of 3.5% from the prior year.
Esperion Therape invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
ESPR Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.1M-52.4% | $168.4M+92.9% | $87.3M+6.0% | $82.4M+26.8% | $65.0M-6.0% | $69.1M+33.9% | $51.6M-30.1% | $73.8M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $9.0M-35.5% | $13.9M-1.5% | $14.1M+95.2% | $7.2M-42.4% | $12.6M+14.4% | $11.0M+5.6% | $10.4M-9.3% | $11.5M |
| SG&A Expenses | $43.1M+4.1% | $41.4M-1.0% | $41.8M+5.9% | $39.5M-8.1% | $43.0M+16.4% | $36.9M-7.6% | $40.0M-9.5% | $44.2M |
| Operating Income | -$6.6M-107.7% | $85.2M+955.8% | -$10.0M-240.4% | $7.1M+132.1% | -$22.1M-399.9% | -$4.4M+72.4% | -$16.0M-721.4% | $2.6M |
| Interest Expense | $19.8M-12.5% | $22.6M+2.7% | $22.1M+7.6% | $20.5M+5.4% | $19.4M+18.3% | $16.4M+8.9% | $15.1M+9.9% | $13.7M |
| Income Tax | $0-100.0% | $1.8M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$25.2M-140.7% | $61.8M+297.3% | -$31.3M-146.2% | -$12.7M+68.5% | -$40.5M-89.8% | -$21.3M+27.8% | -$29.5M+52.3% | -$61.9M |
| EPS (Diluted) | $-0.10 | N/A | $-0.16-166.7% | $-0.06+71.4% | $-0.21 | N/A | $-0.15+54.5% | $-0.33 |
ESPR Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $462.5M-0.7% | $465.9M+28.0% | $364.0M+4.9% | $347.1M+7.1% | $324.0M-5.8% | $343.8M+9.5% | $314.1M-10.8% | $352.3M |
| Current Assets | $459.5M-0.7% | $462.6M+28.3% | $360.5M+5.2% | $342.6M+7.5% | $318.8M-5.7% | $338.0M+9.9% | $307.6M-10.9% | $345.1M |
| Cash & Equivalents | $156.2M-7.0% | $167.9M+81.6% | $92.4M+7.4% | $86.1M-24.9% | $114.6M-20.8% | $144.8M0.0% | $144.7M-23.6% | $189.3M |
| Inventory | $104.2M-0.9% | $105.1M-3.1% | $108.5M-5.2% | $114.5M+15.2% | $99.3M+5.1% | $94.5M+18.0% | $80.1M-5.2% | $84.5M |
| Accounts Receivable | $132.4M-5.6% | $140.2M+17.8% | $119.0M+10.4% | $107.7M+32.5% | $81.3M+1.4% | $80.1M+18.2% | $67.8M+12.4% | $60.4M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $770.5M+0.3% | $767.9M-5.8% | $815.4M+4.5% | $780.6M+4.0% | $750.2M+2.4% | $732.5M+7.0% | $684.3M-1.8% | $696.5M |
| Current Liabilities | $300.4M-0.1% | $300.8M-16.2% | $359.0M+20.2% | $298.8M+10.3% | $271.0M+10.0% | $246.2M+48.4% | $165.9M-5.4% | $175.3M |
| Long-Term Debt | $97.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$307.9M-2.0% | -$302.0M+33.1% | -$451.4M-4.1% | -$433.5M-1.7% | -$426.2M-9.6% | -$388.7M-5.0% | -$370.2M-7.6% | -$344.2M |
| Retained Earnings | -$1.6B-1.6% | -$1.6B+3.7% | -$1.7B-1.9% | -$1.7B-0.8% | -$1.6B-2.5% | -$1.6B-1.3% | -$1.6B-1.9% | -$1.6B |
ESPR Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.7M-161.3% | $45.2M+1155.6% | -$4.3M+86.4% | -$31.4M-38.9% | -$22.6M+35.3% | -$35.0M+1.1% | -$35.3M-390.3% | -$7.2M |
| Capital Expenditures | $189K | $0 | $0 | $0 | $0 | $0-100.0% | $167K+116.9% | $77K |
| Free Cash Flow | -$27.9M-161.7% | $45.2M+1155.6% | -$4.3M+86.4% | -$31.4M-38.9% | -$22.6M+35.3% | -$35.0M+1.5% | -$35.5M-387.4% | -$7.3M |
| Investing Cash Flow | -$189K | $0 | $0 | $0 | $0 | $0+100.0% | -$167K-116.9% | -$77K |
| Financing Cash Flow | $16.2M-46.2% | $30.2M+182.6% | $10.7M+274.5% | $2.9M+138.0% | -$7.5M-121.4% | $35.0M+484.8% | -$9.1M+69.7% | -$30.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ESPR Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -8.2%-58.8pp | 50.6%+62.0pp | -11.4%-20.0pp | 8.6%+42.6pp | -34.0%-27.6pp | -6.4%+24.6pp | -31.0%-34.5pp | 3.5% |
| Net Margin | -31.4%-68.2pp | 36.7%+72.6pp | -35.9%-20.4pp | -15.4%+46.8pp | -62.2%-31.4pp | -30.9%+26.3pp | -57.2%+26.7pp | -83.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.5%-18.7pp | 13.3%+21.9pp | -8.6%-4.9pp | -3.7%+8.8pp | -12.5%-6.3pp | -6.2%+3.2pp | -9.4%+8.2pp | -17.6% |
| Current Ratio | 1.530.0 | 1.54+0.5 | 1.00-0.1 | 1.15-0.0 | 1.18-0.2 | 1.37-0.5 | 1.85-0.1 | 1.97 |
| Debt-to-Equity | -2.50+0.0 | -2.54-0.7 | -1.810.0 | -1.80-0.0 | -1.76+0.1 | -1.88-0.0 | -1.85+0.2 | -2.02 |
| FCF Margin | -34.8%-61.7pp | 26.9%+31.8pp | -4.9%+33.2pp | -38.1%-3.3pp | -34.8%+15.8pp | -50.6%+18.2pp | -68.7%-58.9pp | -9.9% |
Note: Shareholder equity is negative (-$302.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Esperion Therape's annual revenue?
Esperion Therape (ESPR) reported $403.1M in total revenue for fiscal year 2025. This represents a 21.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Esperion Therape's revenue growing?
Esperion Therape (ESPR) revenue grew by 21.3% year-over-year, from $332.3M to $403.1M in fiscal year 2025.
Is Esperion Therape profitable?
No, Esperion Therape (ESPR) reported a net income of -$22.7M in fiscal year 2025, with a net profit margin of -5.6%.
What is Esperion Therape's EBITDA?
Esperion Therape (ESPR) had EBITDA of $60.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Esperion Therape's operating margin?
Esperion Therape (ESPR) had an operating margin of 14.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Esperion Therape's net profit margin?
Esperion Therape (ESPR) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Esperion Therape's free cash flow?
Esperion Therape (ESPR) generated -$13.1M in free cash flow during fiscal year 2025. This represents a 45.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Esperion Therape's operating cash flow?
Esperion Therape (ESPR) generated -$13.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Esperion Therape's total assets?
Esperion Therape (ESPR) had $465.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Esperion Therape's capital expenditures?
Esperion Therape (ESPR) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Esperion Therape spend on research and development?
Esperion Therape (ESPR) invested $47.9M in research and development during fiscal year 2025.
What is Esperion Therape's current ratio?
Esperion Therape (ESPR) had a current ratio of 1.54 as of fiscal year 2025, which is generally considered healthy.
What is Esperion Therape's debt-to-equity ratio?
Esperion Therape (ESPR) had a debt-to-equity ratio of -2.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Esperion Therape's return on assets (ROA)?
Esperion Therape (ESPR) had a return on assets of -4.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Esperion Therape's cash runway?
Based on fiscal year 2025 data, Esperion Therape (ESPR) had $167.9M in cash against an annual operating cash burn of $13.1M. This gives an estimated cash runway of approximately 154 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Esperion Therape's debt-to-equity ratio negative or unusual?
Esperion Therape (ESPR) has negative shareholder equity of -$302.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Esperion Therape's Altman Z-Score?
Esperion Therape (ESPR) has an Altman Z-Score of -2.53, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Esperion Therape's Piotroski F-Score?
Esperion Therape (ESPR) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Esperion Therape's earnings high quality?
Esperion Therape (ESPR) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Esperion Therape cover its interest payments?
Esperion Therape (ESPR) has an interest coverage ratio of 0.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Esperion Therape?
Esperion Therape (ESPR) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.